NCT03318276View on ClinicalTrials.gov

Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

February 20, 2017

Primary Completion Date

October 15, 2018

Study Completion Date

October 15, 2018

Conditions

Peripheral Arterial Disease

Interventions

DRUG

SID142

SID142 is administrated to patients with PAD for 12 weeks

DRUG

Rinexin® Tab

Rinexin® Tab is administrated to patients with PAD for 12 weeks

Trial Locations (1)

Unknown

Yonsei University College of Medicine, Severance Cardiovascular Hospital, Seoul

All Listed Sponsors

lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT03318276 - Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease | Biotech Hunter | Biotech Hunter